Randomized Clinical Trials and Real World Prospective Observational Studies on Bevacizumab, PARP Inhibitors, and Immune Checkpoint Inhibitors in the First-Line Treatment of Advanced Ovarian Carcinoma: A Critical Review
| Autor: | Angiolo Gadducci, Stefania Cosio |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Bevacizumab Chemotherapy Immune-check point inhibitors Niraparib Olaparib Ovarian carcinoma PARP-inhibitors Review Antineoplastic Combined Chemotherapy Protocols Carcinoma Ovarian Epithelial Female Humans Immune Checkpoint Inhibitors Observational Studies as Topic Ovarian Neoplasms Poly(ADP-ribose) Polymerase Inhibitors Randomized Controlled Trials as Topic Cancer Research medicine.medical_specialty medicine.medical_treatment law.invention chemistry.chemical_compound Randomized controlled trial law Ovarian Epithelial Internal medicine medicine business.industry Carcinoma General Medicine Regimen chemistry Concomitant Observational study business medicine.drug |
| Zdroj: | Anticancer Research. 41:4673-4685 |
| ISSN: | 1791-7530 0250-7005 |
| Popis: | Platinum/paclitaxel-based chemotherapy is able to obtain a clinical response in up to 80% of patients with advanced ovarian carcinoma, but most of them will subsequently develop recurrent disease. Several therapeutic approaches, including prolonged administration of the first-line regimen and the concomitant or sequential addition of a third cytotoxic agent to standard chemotherapy, failed to improve the clinical outcome of patients. In the last years, the implementation of the biological knowledge on ovarian carcinoma and the introduction of bevacizumab (BEV) and poly(ADP-ribose) polymerase inhibitors (PARPi) in first-line treatment have improved patient prognosis. In this review, we have analyzed the randomized clinical trials and real world observational studies on these issues, with the aim to suggest an algorithm for a rational use of BEV and PARPi in patients with newly diagnosed advanced ovarian carcinoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|